Premature termination codon mutations in ABCA7 contribute to Alzheimer's disease risk in Belgian patients.


Journal

Neurobiology of aging
ISSN: 1558-1497
Titre abrégé: Neurobiol Aging
Pays: United States
ID NLM: 8100437

Informations de publication

Date de publication:
10 2021
Historique:
received: 19 11 2020
revised: 31 03 2021
accepted: 23 04 2021
pubmed: 7 6 2021
medline: 1 1 2022
entrez: 6 6 2021
Statut: ppublish

Résumé

The ATP-Binding Cassette Subfamily A Member 7 gene (ABCA7) was identified as a risk gene for Alzheimer's disease (AD) in genome-wide association studies of large cohorts of late-onset AD (LOAD) patients. Extended resequencing of the ABCA7 coding regions identified mutations that lead to premature termination codons (PTC) and loss of function of ABCA7. PTC mutations were enriched in LOAD patients and were frequently present in patients with early-onset AD (EOAD). We aimed at assessing the contribution of ABCA7 PTC mutations to AD in the Belgian population by screening the ABCA7 coding region in a Belgian AD cohort of 1376 patients, including LOAD and EOAD patients, and in a Belgian control cohort of 976 individuals. We identified a PTC mutation in 67 AD patients (4.9%) and in 18 control individuals (1.8%) confirming the enrichment of ABCA7 PTC mutations in Belgian AD patients. The patient carriers had a mean onset age of 69.7 ± 9.8 years with a wide onset age range of 42 years (48-90 years). In 77.3% of the families of ABCA7 carriers, there were AD patients present suggestive of a positive family history of disease, but a Mendelian co-segregation of ABCA7 PTC mutations with disease is not clear. Overall, our genetic data predict that PTC mutations in ABCA7 are common in the Belgian population and are present in LOAD and EOAD patients.

Identifiants

pubmed: 34090711
pii: S0197-4580(21)00146-9
doi: 10.1016/j.neurobiolaging.2021.04.023
pii:
doi:

Substances chimiques

ABCA7 protein, human 0
ATP-Binding Cassette Transporters 0
Codon 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

307.e1-307.e7

Informations de copyright

Copyright © 2021. Published by Elsevier Inc.

Auteurs

Liene Bossaerts (L)

Neurodegenerative Brain Diseases Group, VIB Center for Molecular Neurology, Antwerp, Belgium; Institute Born-Bunge, Antwerp, Belgium; Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium.

Elisabeth Hens (E)

Neurodegenerative Brain Diseases Group, VIB Center for Molecular Neurology, Antwerp, Belgium; Institute Born-Bunge, Antwerp, Belgium; Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium; Department of Neurology, University Hospital Antwerp, Edegem, Belgium; Department of Neurology and Memory Clinic, Hospital Network Antwerp, Antwerp, Belgium; Department of Neurology, University Hospital Brussels, and University Center for Neurosciences, VUB, Brussels, Belgium.

Bernard Hanseeuw (B)

Department of Neurology, University Hospitals Saint-Luc Brussels and University Institute of Neuroscience, UC Louvain, Louvain-la-Neuve, Belgium.

Rik Vandenberghe (R)

Department of Neurology, University Hospitals Leuven and University Department of Neurosciences KU Leuven, Leuven, Belgium.

Patrick Cras (P)

Institute Born-Bunge, Antwerp, Belgium; Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium; Department of Neurology, University Hospital Antwerp, Edegem, Belgium.

Peter P De Deyn (PP)

Institute Born-Bunge, Antwerp, Belgium; Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium; Department of Neurology and Memory Clinic, Hospital Network Antwerp, Antwerp, Belgium.

Sebastiaan Engelborghs (S)

Institute Born-Bunge, Antwerp, Belgium; Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium; Department of Neurology, University Hospital Brussels, and University Center for Neurosciences, VUB, Brussels, Belgium.

Christine Van Broeckhoven (C)

Neurodegenerative Brain Diseases Group, VIB Center for Molecular Neurology, Antwerp, Belgium; Institute Born-Bunge, Antwerp, Belgium; Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium. Electronic address: christine.vanbroeckhoven@uantwerpen.vib.be.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH